Search

everythinglearnresearchcommunity

for

Search:↓

Men with baldness at the front and top of their head at age 45 may have a higher risk of aggressive prostate cancer.

African American men with prostate cancer have more androgen receptor mutations, which may lead to more aggressive cancer compared to Caucasian American men.

Early-onset baldness is linked to a higher risk of aggressive prostate cancer in African-American men, especially before age 60.

Finasteride for hair loss is safe and does not increase the risk of high-grade prostate cancer.

2007 research improved understanding of prostate cancer risk, diagnosis, and treatment, but also showed the need for personalized treatment and further study on certain therapies' risks.

Case-only trees and random forests improve predictions of treatment effects in clinical trials.

Men with more advanced male pattern baldness have a higher risk of prostate cancer and more severe disease.

Low testosterone does not prevent prostate cancer in men with type 1 diabetes.

Serum triglyceride levels are not linked to prostate cancer risk.

Using a single PSA level to decide on a prostate biopsy is not effective; a more personalized approach considering various factors is recommended.

Being obese and eating too many calories may increase the risk of kidney cancer, but physical activity doesn't seem to affect this risk.

Long-term diabetes is linked to lower prostate cancer risk.

Higher BMI is linked to a lower risk of non-aggressive prostate cancer and a higher risk of aggressive prostate cancer.

Finasteride is popular for treating male hair loss but may increase the risk of serious prostate cancer and has other potential side effects.

Medications have become the main treatment for enlarged prostate symptoms, replacing surgery and watchful waiting.

Men who experienced baldness at age 20 may have double the risk of getting prostate cancer.

Certain genetic variants increase the risk of resistance to hormone therapy in prostate cancer patients.

Finger length ratio may indicate male hair loss.

Blocking the enzyme 5α-reductase can shrink the prostate and help treat enlarged prostate issues.

The document concludes that the 5 alpha-reductase enzymes are important in steroid metabolism and related to various human diseases, with inhibitors used to treat conditions like male pattern baldness and prostate issues.

Minoxidil and finasteride treat hair loss in men, while minoxidil treats hair loss in women.

Early diagnosis and treatment, using finasteride, minoxidil, or hair transplantation, improves hair loss outcomes.

Inhibiting 5α-reductase can help reduce prostate cancer risk and improve treatment.

Dutasteride 0.5 mg works better than finasteride and placebo for increasing hair in men with hair loss.

Taking 1 mg/day finasteride for hair loss significantly lowers PSA levels in men, which may affect prostate cancer screening.

Doxil showed some effectiveness against advanced prostate cancer but caused severe side effects at higher doses.

A new gene, JMJD1C, may affect testosterone levels in men.

E211 G>A gene linked to lower risk of severe prostate cancer and hair loss.

Minoxidil and finasteride are effective for male hair loss, minoxidil for female hair loss, and various treatments like corticosteroids work for alopecia areata; treatment should be tailored to the individual.

S5αR inhibitors might help treat schizophrenia and other mental disorders but need more research.